Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on novel serotonergic agonists for mental health disorders, has appointed Michael Cola as Chief Executive Officer, effective immediately. The announcement comes as the company prepares for significant clinical milestones, including expected Phase 2 data for HLP004 in generalized anxiety disorder this quarter and Phase 3 topline data for HLP003 in major depressive disorder in Q4 2026.
Cola brings extensive experience in the pharmaceutical industry, having previously held leadership roles at major biopharmaceutical companies. His appointment signals Helus Pharma's strategic shift toward later-stage development, regulatory engagement, and commercial planning. The company is also expanding its global intellectual property portfolio, which includes proprietary novel serotonergic agonists (NSAs) designed to activate serotonin pathways and promote neuroplasticity.
HLP003, a proprietary NSA for major depressive disorder, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential to address unmet needs in mental health treatment. HLP004 is being developed for generalized anxiety disorder, and the company has an extensive research pipeline of investigational NSAs.
Helus Pharma, operating as the commercial name of Cybin Inc. since 2019, operates in Canada, the United States, the United Kingdom, and Ireland. The company aims to improve the treatment landscape with NSA therapies that provide durable improvements in mental health. For more information, visit www.helus.com or follow the team on social media platforms.
The full press release is available at https://ibn.fm/VugQZ. For the latest news on Helus Pharma, visit the company's newsroom at https://ibn.fm/HELP.
